Interleukin-6 receptor antagonists in critically ill patients with Covid-19–preliminary report
Remap-Cap Investigators, AC Gordon, PR Mouncey… - Medrxiv, 2021 - medrxiv.org
Background The efficacy of interleukin-6 receptor antagonists in critically ill patients with
coronavirus disease 2019 (Covid-19) is unclear. Methods We evaluated tocilizumab and
sarilumab in an ongoing international, multifactorial, adaptive platform trial. Adult patients
with Covid-19, within 24 hours of commencing organ support in an intensive care unit, were
randomized to receive either tocilizumab (8mg/kg) or sarilumab (400mg) or standard care
(control). The primary outcome was an ordinal scale combining in-hospital mortality …
coronavirus disease 2019 (Covid-19) is unclear. Methods We evaluated tocilizumab and
sarilumab in an ongoing international, multifactorial, adaptive platform trial. Adult patients
with Covid-19, within 24 hours of commencing organ support in an intensive care unit, were
randomized to receive either tocilizumab (8mg/kg) or sarilumab (400mg) or standard care
(control). The primary outcome was an ordinal scale combining in-hospital mortality …
[HTML][HTML] Interleukin-6 receptor antagonists in critically ill patients with Covid-19
Remap-Cap Investigators - New England Journal of Medicine, 2021 - Mass Medical Soc
Background The efficacy of interleukin-6 receptor antagonists in critically ill patients with
coronavirus disease 2019 (Covid-19) is unclear. Methods We evaluated tocilizumab and
sarilumab in an ongoing international, multifactorial, adaptive platform trial. Adult patients
with Covid-19, within 24 hours after starting organ support in the intensive care unit (ICU),
were randomly assigned to receive tocilizumab (8 mg per kilogram of body weight),
sarilumab (400 mg), or standard care (control). The primary outcome was respiratory and …
coronavirus disease 2019 (Covid-19) is unclear. Methods We evaluated tocilizumab and
sarilumab in an ongoing international, multifactorial, adaptive platform trial. Adult patients
with Covid-19, within 24 hours after starting organ support in the intensive care unit (ICU),
were randomly assigned to receive tocilizumab (8 mg per kilogram of body weight),
sarilumab (400 mg), or standard care (control). The primary outcome was respiratory and …